This Article Abstract Full Text (PDF) Data Supplement All Versions of this Article: 110/19/3028    most recent 01.CIR.0000147187.78162.ACv1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Le Bouter, S. Articles by Demolombe, S. Search for Related Content PubMed PubMed Citation Articles by Le Bouter, S. Articles by Demolombe, S. Related Collections Functional genomics Ion channels/membrane transport Physiological and pathological control of gene expression

(Circulation. 2004;110:3028-3035.)
© 2004 American Heart Association, Inc.

Arrhythmia/Electrophysiology

Long-Term Amiodarone Administration Remodels Expression of Ion Channel Transcripts in the Mouse Heart

Sabrina Le Bouter, MSc; Aziza El Harchi, MSc; Céline Marionneau, MSc; Chloé Bellocq, MSc; Arnaud Chambellan, MD; Toon van Veen, PhD; Christophe Boixel, PhD; Bruno Gavillet, MSc; Hugues Abriel, MD, PhD; Khai Le Quang, MD; Jean-Christophe Chevalier, MD; Gilles Lande, MD; Jean J. Léger, PhD; Flavien Charpentier, PhD; Denis Escande, MD, PhD; Sophie Demolombe, PhD

From l’Institut du thorax—INSERM U533 (S.L.B., A.E.H., C.M., C.B., A.C., K.L.Q., J.C.C., G.L., J.J.L., F.C., D.E., S.D.), Faculté de Médecine, Nantes, France; the Department of Medical Physiology (T.V.V.), University Medical Center, Utrecht, The Netherlands; and Institut de Pharmacologie (C.B., B.G, H.A.), Lausanne, Switzerland.

Correspondence to Sophie Demolombe, INSERM U533, Faculté de Médecine, 1 rue G. Veil, 44035 Nantes Cedex, France. E-mail sophie.demolombe{at}nantes.inserm.fr

Received June 15, 2004; revision received August 4, 2004; accepted August 19, 2004.

	Abstract

Top Abstract Introduction Methods Results Discussion References

 
Background— The basis for the unique effectiveness of long-term amiodarone treatment on cardiac arrhythmias is incompletely understood. The present study investigated the pharmacogenomic profile of amiodarone on genes encoding ion-channel subunits.

Methods and Results— Adult male mice were treated for 6 weeks with vehicle or oral amiodarone at 30, 90, or 180 mg · kg^–1 · d^–1. Plasma and myocardial levels of amiodarone and N-desethylamiodarone increased dose-dependently, reaching therapeutic ranges observed in human. Plasma triiodothyronine levels decreased, whereas reverse triiodothyronine levels increased in amiodarone-treated animals. In ECG recordings, amiodarone dose-dependently prolonged the RR, PR, QRS, and corrected QT intervals. Specific microarrays containing probes for the complete ion-channel repertoire (IonChips) and real-time reverse transcription–polymerase chain reaction experiments demonstrated that amiodarone induced a dose-dependent remodeling in multiple ion-channel subunits. Genes encoding Na⁺ (SCN4A, SCN5A, SCN1B), connexin (GJA1), Ca²⁺ (CaCNA1C), and K⁺ channels (KCNA5, KCNB1, KCND2) were downregulated. In patch-clamp experiments, lower expression of K⁺ and Na⁺ channel genes was associated with decreased I_to,f, I_K,slow, and I_Na currents. Inversely, other K⁺ channel - and ß-subunits, such as KCNA4, KCNK1, KCNAB1, and KCNE3, were upregulated.

Conclusions— Long-term amiodarone treatment induces a dose-dependent remodeling of ion-channel expression that is correlated with the cardiac electrophysiologic effects of the drug. This profile cannot be attributed solely to the amiodarone-induced cardiac hypothyroidism syndrome. Thus, in addition to the direct effect of the drug on membrane proteins, part of the therapeutic action of long-term amiodarone treatment is likely related to its effect on ion-channel transcripts.

Key Words: antiarrhythmic agents • ion channels • molecular biology • electrophysiology

	Introduction

Top Abstract Introduction Methods Results Discussion References

 
Amiodarone, a widely used antiarrhythmic drug, has remarkable efficacy for the treatment of ventricular tachyarrhythmias and atrial fibrillation. However, the basis for its effectiveness is still poorly understood. The pharmacologic profile of this drug is complex, and much remains to be clarified about both short- and long-term actions. Amiodarone has been referred to as a class III antiarrhythmic agent,¹ but it also possesses electrophysiologic characteristics of class I and IV agents and minor class II effects.² The drug is also known to modify thyroid function extensively because of its iodinated nature.³

The question arose as to whether the long-term effects of amiodarone might stem from its molecular interaction with thyroid hormone receptors or other mechanisms. In particular, it has been hypothesized that the effects of amiodarone could depend on modulation of transcript expression in addition to its direct effect on cell membrane channels.⁴ Genomic techniques now bring gene expression studies to a genome scale, allowing investigators to examine simultaneous changes in the expression of the complete gene repertoire. We have developed a specific cDNA microarray (IonChip) containing probes for virtually all known mouse and human ion-channel genes (- and ß-subunits).⁵ With this new tool, our previous investigation explored ion-channel remodeling as produced by altered thyroid status in the mouse heart.⁵ We now evaluate the effects of long-term amiodarone treatment on global ion-channel expression. Our data show that long-term amiodarone treatment dose-dependently remodels ion-channel expression. Remodeling, which includes downexpression of K⁺ channel genes and of genes involved in conduction, coincides with the dose-dependent effects of amiodarone on mouse cardiac conduction velocity and repolarization. We propose that in addition to the well-known direct effect of the drug on membrane proteins, part of the action of amiodarone on the heart is related to its pharmacogenomic profile.

	Methods

Top Abstract Introduction Methods Results Discussion References

 
An expanded Methods section containing details for microarray, relative quantitative reverse transcription–polymerase chain reaction (RT-PCR), and functional studies and statistical analysis is available in the online-only Data Supplement.

Animal experiments were performed in accordance with institutional guidelines for animal use in research. Ten-week-old male C57BL/6 mice (Iffa Credo, l’Arbresle, France) were used. Mice were treated for 6 weeks with 3 doses of amiodarone (a gift from Dr Patrick Gautier, Sanofi-Synthelabo, Montpellier, France): 30, 90, and 180 mg · kg^–1 · d^–1. Sham animals received the same food without amiodarone. The study included 54 sham mice and 18 mice in each amiodarone group. IonChip contained 208 probes representing most mouse ion-channel subunits and connexins cloned so far. The complete probe list can be found at http://www.nantes.inserm.fr/u533.

	Results

Top Abstract Introduction Methods Results Discussion References

 
Effects of Long-Term Amiodarone Treatment on Functional Parameters
Plasma and myocardial levels of amiodarone and N-des- ethylamiodarone (DEA) were measured in sham and treated animals. As illustrated in Figure 1, there was a clear dose-dependent increase in plasma and tissue amiodarone levels. The 180 mg · kg^–1 · d^–1 amiodarone group was significantly different from the 90 mg · kg^–1 · d^–1 group, which in turn was significantly different from the 30 mg · kg^–1 · d^–1 group. With DEA, 180 mg · kg^–1 · d^–1 amiodarone was required to reach detectable levels in the plasma (Figure 1A). DEA accumulated dose-dependently in cardiac tissue (Figure 1B).

View larger version (30K): [in this window] [in a new window]   Figure 1. Amiodarone and DEA in plasma (A) and cardiac tissue (B) from sham and amiodarone-treated mice. Measurements were performed on 6 distinct pools, each from 3 mice. Data are mean±SEM *P<0.05, **P<0.01, ***P<0.0001 vs corresponding lower-dose group. Abbreviations are as defined in text.

As shown in Table 1, mice treated with amiodarone at 90 and 180 mg · kg^–1 · d^–1 had decreased body and heart weights, although their heart weight–to–body weight ratios were not significantly different from sham. As expected, 6-week amiodarone treatment induced a decrease in plasma triiodothyronine and an increase in reverse triiodothyronine. This effect reached significance for the 90 and 180 but not for the 30 mg · kg^–1 · d^–1 dose groups.

View this table: [in this window] [in a new window]   TABLE 1. Body Weight, Heart Weight, Heart Weight:Body Weight Ratio, Plasma T3, and Plasma Reverse T3 in Sham and Amiodarone-Treated Groups

Representative ECG recordings from sham and amiodarone-treated mice are illustrated in Figure 2A. As is evident, the 180 mg · kg^–1 · d^–1 dose prolonged the P-wave duration and the RR, PR, QRS, and QT intervals. Average data reported in Table 2 show that the heart rate and conduction velocity (PR and QRS intervals) were significantly affected by the 90 mg · kg^–1 · d^–1 dose. In contrast, 90 mg · kg^–1 · d^–1 amiodarone did not prolong the corrected QT. Thus, conduction was slowed by both the 90 and 180 mg · kg^–1 · d^–1 doses of amiodarone, whereas repolarization was prolonged by the 180 mg · kg^–1 · d^–1 dose only. The lowest dose of 30 mg · kg^–1 · d^–1 had no significant effect on ECG parameters. Intraventricular recordings as illustrated in Figure 2B showed that the prolonged PR interval observed with the 90 and 180 mg · kg^–1 · d^–1 doses was related to an intranodal conduction defect (AH [atrial-His bundle interval]=46±2 and 55±4 ms, respectively, vs 36±2 ms in sham; P<0.005; n=6 animals per group), as well as a His bundle conduction defect (HV [His bundle-ventricular interval]=14±1 and 21±2 ms, respectively, vs 10±1 ms in sham; P<0.005). Atrioventricular Wenckebach cycle length was increased from 96±9 ms in sham to 146±9 ms or 181±17 ms (P<0.005) in mice receiving 90 or 180 mg · kg^–1 · d^–1 amiodarone, respectively.

View larger version (18K): [in this window] [in a new window]   Figure 2. Typical ECGs (lead I) recordings (A) and in vivo intracardiac electrogram recordings of atrioventricular conduction parameters (B) in sham and amiodarone-treated mice. A indicates atrial; H, His bundle; and V, ventricular deflections. Other abbreviations are as defined in text.

View this table: [in this window] [in a new window]   TABLE 2. Comparison of ECG Parameters From Sham and Amiodarone- Treated Mice

Effects of Long-Term Amiodarone Treatment on Cardiac Ion-Channel Transcripts
cDNA microarrays were used to screen cardiac RNA samples from sham and amiodarone-treated (180 mg · kg^–1 · d^–1) mice. Figure 3 represents the percentage variation of a list of control genes in the 180 mg · kg^–1 · d^–1 group versus sham. Downregulation of cardiac thyroid hormone 1-receptor (THRA1) mRNA was previously reported in mice⁶ and rats.⁷ THRA2 and/or THRA3 mRNA was downregulated, whereas THRB was unaffected. Downregulation of phospholipase A2 coincided with its decreased activity under amiodarone treatment.⁸ Upregulation of nitric oxide synthase occurred in accordance with its activation by amiodarone in human veins,⁹ whereas downregulation of sphingomyelinase (SMPD1) coincided with its decreased activity in mouse pulmonary endothelial cells.¹⁰ CD4, CD8A, interleukin-1, and interleukin-6 were used as negative controls.

View larger version (20K): [in this window] [in a new window]   Figure 3. Effects of amiodarone on 10 control genes. Percentage variation in cardiac expression as evaluated by cDNA microarrays in mice receiving 180 mg · kg–1 · d–1 amiodarone vs sham is shown. Data are mean±SEM of 6 to 8 values from 8 different chips. *P<0.005 as evaluated with SAM (significance analysis of microarrays). PLA indicates phospholipase A; NOS, nitric oxide synthase; and IL, interleukin. All other abbreviations are as defined in text.

Figure 4 illustrates the effects of long-term amiodarone treatment on ion-channel expression. For clarity, only transcripts expressed in the mouse heart are shown. Among the differentially expressed ion-channel subunits were genes involved in cardiac conduction, such as sodium channels - and ß-subunits (SCN4A, SCN5A, and SCN1B) and connexin 43 (GJA1), which were downregulated. Western blot experiments showed that these modifications were correlated with decreased protein amounts of Nav1.5 (SCN5A) and connexin 43 (data not shown). Calcium homeostasis was affected by amiodarone, with downregulation of Cav1.2 channels (CACNA1C) and Cavß1- and Cavß2-subunits (CACNB1 and CACNB2). In addition, the type I sodium-calcium exchanger (SLC8A1), type II calsequestrin (CASQ2), and type III calmodulin (CALM3) were downregulated. The voltage-gated potassium channel genes involved in mouse cardiac repolarization, Kv2.1 (KCNB1), Kv1.5 (KCNA5), and Kv4.2 (KCND2), were downregulated, whereas Kv1.4 (KCNA4) and regulatory subunits such as Kvß1 (KCNAB1), MiRP1 (KCNE2), and MiRP2 (KCNE3) were upregulated. Two-pore potassium channels, including TWIK-1 (KCNK1), and TASK-2 (KNCK5), and the intermediate/small-conductance calcium-activated potassium channel (KCNN2) were upregulated. It should be noted, however, that these latter genes are expressed at a low level in the mouse heart. Inversely, mRNA expression for Kir6.2 (KCNJ11) and SUR2 (ABCC9) forming ATP-sensitive K⁺ channels were downregulated. This was also observed for the two-pore K⁺ channel gene TASK (KCNK3).

View larger version (36K): [in this window] [in a new window]   Figure 4. Effects of amiodarone on cardiac ion-channel transcripts. Bars show percentage variation in cardiac expression as evaluated by cDNA microarrays in mice receiving 180 mg · kg–1 · d–1 amiodarone vs sham. Na+ ch indicates Na+ channel subunits; Ca2+ ch, Ca2+ channel subunits; Ca2+ reg, proteins involved in Ca2+ regulation; Cl– ch, Cl– channel subunits; and Cnx, connexins. KCND3L (AF107781) and KCND3 mol/L (AF107782) are 2 alternatively spliced isoforms. Data are mean±SEM of 6 to 8 values from 8 different chips. *P<0.005 as evaluated with SAM. All other abbreviations are as defined in text.

We used real-time PCR to confirm differential expression of 18 selected genes and also to explore dose dependence (Figure 5). The results show excellent qualitative correlation between microarray and PCR data. As previously observed,⁵ however, comparison of the obtained fold changes with microarray analysis versus real-time PCR revealed larger differences with the latter approach. For example, SCN5A transcripts decreased by 40% (180 mg · kg^–1 · d^–1 dose) in real-time PCR experiments, whereas changes detected with the microarrays, though significant, were 20%. Most important, real-time PCR data showed that long-term amiodarone treatment dose-dependently regulated the expression of a large set of ion channels. Interestingly, the 30 mg · kg^–1 · d^–1 dose, which did not affect the surface ECG, produced no effect on ion-channel expression. Finally, genes targeted as nonvariant by microarray analysis, such as GJA5, KCNE1, and KCNQ1, were also nonvariant in real-time PCR analysis.

View larger version (29K): [in this window] [in a new window]   Figure 5. Relative quantitative RT-PCR evaluation of effects of amiodarone on cardiac expression of selected channel subunits. Percentage variation in mice receiving 30 (open bars), 90 (gray bars), and 180 mg · kg–1 · d–1 (filled bars) amiodarone vs sham mice. Fluorescence signals were normalized to acidic ribosomal phosphoprotein P0 (Arbp) gene, used as reference. Data are mean±SEM of 6 to 10 measurements. *P<0.001 vs Arbp. All other abbreviations are as defined in text.

Functional Correlation With Molecular Data
Whole-cell patch-clamp recordings were conducted in ventricular myocytes isolated from sham and 180 mg · kg^–1 · d^–1 amiodarone–treated hearts. As illustrated in Figure 6A, the amplitude of the transient outward current I_to was reduced significantly in the amiodarone-treated group. This was correlated with the observed downregulation of Kv4.2 (KCND2) expression. Similarly, the density of the current remaining at the end of 400-ms pulses, which reflects I_K,slow,¹¹ was also significantly decreased, in accordance with the reduced expression of Kv1.5 (KCNA5) and Kv2.1 (KCNB1). By contrast, the density of the steady-state current remaining at the end of 4-second pulses, I_ss,¹¹ was not modified by long-term amiodarone treatment (2.94±0.47 vs 2.52±0.32 pA/pF at +50 mV in sham and amiodarone-treated myocytes, respectively; not illustrated). The amplitude of the inwardly rectifying background K⁺ current I_K1 was not affected (Figure 6B), which was correlated with the molecular data, because neither Kir2.1 (KCNJ2) nor Kir2.2 (KCNJ12) mRNA was affected in amiodarone-treated mice. Voltage-clamp experiments further revealed that the peak inward sodium current (I_Na) decreased by 33±6 pA/pF (P<0.001) in amiodarone-treated myocytes (Figure 6C). These data are also correlated with the reduced expression of SCNA5 mRNA in microarrays. Surprisingly, the L-type calcium current density was unmodified in treated mice (data not shown), contrasting with the 50% reduced expression of CACNA1C in real-time RT-PCR experiments.

View larger version (26K): [in this window] [in a new window]   Figure 6. Effects of long-term amiodarone administration (180 mg · kg–1 · d–1) on (A) voltage-gated K+ currents, (B) inward rectifier K+ current, and (C) voltage-gated Na+ current from ventricular myocytes. For each panel, representative current recordings and corresponding current-voltage relations are shown (data from sham, open symbols; amiodarone-treated mice, filled symbols). A, Currents were elicited by 400-ms voltage steps between –40 and +50 mV in 10-mV increments from holding potential (HP) of –70 mV. Current traces recorded at –30, –10, +10, +30, and +50 mV are shown. Bottom, Current-voltage relations for peak transient (Ito, circles) and sustained (IKslow, squares) K+ currents recorded in myocytes from sham (14 cells from 6 mice) and treated (17 cells from 5 mice) mice. B, Inward rectifier K+ current, IK1, was elicited by 500-ms voltage steps between –110 and –20 mV in 10-mV increments. HP was –70 mV. Bottom, Current-voltage relations for IK1. Sham, 7 cells from 3 mice; amiodarone, 9 cells from 3 mice. C, Na+ current, INa, was elicited by 20-ms voltage steps between –90 and 0 mV in 5-mV increments. HP was –120 mV. Bottom, Current-voltage relations for INa. Sham, 11 cells from 5 mice; amiodarone, 10 cells from 5 mice. *P<0.05, **P<0.01, *** P<0.001 vs sham. All other abbreviations are as defined in text.

	Discussion

Top Abstract Introduction Methods Results Discussion References

 
The present study shows that amiodarone dose-dependently remodels cardiac ion-channel expression and that remodeling is correlated with the cardiac electrophysiologic effects of the drug, ie, slowed conduction (decreased SCN5A, SCN4A, and GJA1 expression) and prolonged repolarization (decreased KCND2, KCNB1, and KCNA5 expression). These gene expression modifications impact the corresponding current density and/or protein level. Importantly, the prolongation of cardiac repolarization induced by 180 mg · kg^–1 · d^–1 amiodarone was associated with a complex rearrangement of several repolarizing K⁺ channel genes. These include not only decreased expression of the major K⁺ channels involved in mouse cardiac repolarization but also increased expression of other K⁺ channel subunits (KCNA4, KCNAB1, KCNE2, and KCNE3). We previously observed a comparable rearrangement in the same mouse model under the effects of hypothyroism.⁵ To our knowledge, this is the first large-scale study showing pharmacogenomic effects of an antiarrhythmic drug, which at least partly account for the control of mouse cardiac electrical function by amiodarone and potentially for its antiarrhythmic action, in addition to the known direct effect of the drug on membrane proteins.

Comparison With Previous Studies
Despite the high doses of amiodarone administered to mice, plasma and myocardial concentrations remained within the therapeutic range observed in patients.^12,13 One difference with the clinical situation is the low level of DEA plasma and myocardial concentrations, which never exceeded 0.3 time the parent compound, whereas in humans, concentrations of DEA can be as high as 3 times those of amiodarone. This is consistent with previous observations in animal studies^14–16 and is probably related to species differences in liver metabolism.

In our model, long-term amiodarone treatment induced a dose-dependent bradycardia and a decrease in conduction velocity, in agreement with previous clinical and experimental findings.¹⁷ The small but significant increase in corrected QT at the highest dose of amiodarone is also consistent with the 5% to 18% increase obtained in different animal models treated orally for the same period of time.^18,19 In humans, the prolongation of repolarization rarely exceeds 10% to 15%, as assessed with surface ECG²⁰ or monophasic action potential (MAP) recording.^21,22

Early on, Drvota and coworkers⁴ performed in vitro experiments suggesting that the effects of DEA on cardiac electrical activity could depend on gene expression. In their extensive 1997 review, Kodama et al¹⁵ also reported earlier results from their group, showing a decreased expression of Kv1.5 (KCNA5) in rats treated with amiodarone. Our results show that remodeling affects every gene family represented on our microarrays. As previously mentioned, amiodarone induced a prolongation of ventricular repolarization that can be explained by the decrease in I_to and I_K,slow current densities. A decrease in I_to density without alteration in its voltage dependence has already been described in different models^23,24 and can be explained partly by the decreased expression of Kv4.2 (KCND2). Similarly, the decreased expressions of Kv2.1 (KCNB1) and to a lesser extent of Kv1.5 (KCNA5) are consistent with the reduction of I_K,slow. In the rat, I_sus, a current similar to I_K,slow, is also decreased by long-term amiodarone,²³ probably because of the decreased expression in Kv1.5 (KCNA5).¹⁵ Finally, a previous study in rabbits has shown that long-term amiodarone administration decreases the I_Ks current density without affecting KCNQ1 or KCNE1 mRNA.²⁵ We observed that Ca²⁺ channel subunits, including Cav1.2 that forms the pore of the myocardial L-type Ca²⁺ channel (I_Ca,L), are downregulated in treated mice, consistent with previous binding studies.²⁶ At the functional level, however, previous results are conflicting, because I_Ca,L has been shown to be either decreased or increased¹⁵ by long-term amiodarone administration. In our model, the I_Ca,L current density was unaffected by amiodarone. This finding opposes the decreased expression of CACNA1C, suggesting either posttranscriptional or/and translational mechanisms or compensatory adaptation linked to the expression of CACNB1 and CACNB2 regulatory subunits. In fact, we found that the expression of the regulatory subunit was largely altered by amiodarone. Because these regulatory proteins can exert close control of current amplitude,²⁷ the correlation between changes in gene expression and function may not be straightforward.

Potential Mechanisms for Amiodarone-Induced Ionic Remodeling
The mechanism of the relation between oral amiodarone dose and gene expression is principally unknown. Some genes (ie, SCN5A, GJA1, etc) show progressive remodeling in relation to dose, whereas others (ie, CACNA1C, KCNA4, etc) do not. Different nonexclusive hypotheses can explain ionic remodeling, including (1) the hypothyroidism syndrome induced by amiodarone, (2) a direct effect of amiodarone/DEA on gene promoters, (3) an effect of amiodarone/DEA on transcription factors, and (4) physiologic alterations induced by direct effects of the drug on membrane proteins.

Amiodarone is a diiodinated benzofuran derivative that presents structural similarities to thyroid hormones.²⁸ Cardiac electrophysiologic changes induced by long-term amiodarone closely resemble those induced by hypothyroidism (for a review, see Kodama et al¹⁵). However, hypothyroidism does not mimic all amiodarone long-term effects.^29,30 Recently, Bosh et al³⁰ have shown that hypothyroidism and long-term amiodarone have different effects on guinea pig cardiac K⁺ currents and that their combination prolongs repolarization to a greater extent than either alone. Our study also suggests that amiodarone-induced ionic remodeling cannot be explained by hypothyroidism alone. Indeed, although some of the variations in transcripts induced by long-term amiodarone treatment are similar to those induced by hypothyroidism in the same mouse model,⁵ eg, the decreased expression of KCNA5, KCNB1, or KCND2, the expression of several genes such as GJA1, KCNA4, KCNAB1, and KCNJ11 that are not regulated by thyroid function appear to be regulated by amiodarone. In addition, genes such as CACNA1C, SLC8A1, KCNE1, and KCNQ1 were upregulated by hypothyroidism, whereas others were downregulated (CACNA1C, SLC8A1) or unmodified (KCNE1, KCNQ1) by amiodarone. Finally, nongenomic effects of thyroid hormones are not inhibited by amiodarone.^29,30 Thus, it is not surprising that long-term amiodarone treatment causes remodeling of ion channels different from those associated with systemic hypothyroidism.

One can also speculate that amiodarone can directly modify gene expression. Amiodarone, or most probably DEA, may interfere with nuclear receptor/coactivator interaction.^31,32 It reduces basal LDL receptor promoter activity. It also disrupts the interaction between the glucocorticoid receptor interacting protein-1 and the thyroid hormone receptor ß1.

Alternatively, ionic remodeling could be a long-term consequence of the effects of amiodarone on ionic-channel proteins and could result from an adaptation of the myocytes to a new physiologic steady state. This hypothesis seems least plausible. If true, one would expect, for instance, compensatory overexpression of Na⁺ and Ca²⁺ channel subunits that are major targets of short-term amiodarone treatment, rather than downexpression, as observed in our model.

Clinical and Physiologic Implications
Our results contribute to understanding of the unique profile of amiodarone in the treatment of arrhythmias and may account for the long-term effects of the drug, which differ from its short-term effects. However, their clinical relevance remains unclear for at least 2 reasons: (1) the choice of species dictated by the availability of extensive genomic information and (2) the absence of primary cardiac pathology with or without arrhythmias. It is therefore essential to investigate whether remodeling is also observed in humans and how it interferes with the remodeling resulting from cardiac pathologies.

	Acknowledgments

 
This study was supported by special grants from Ouest-genopole, INSERM, CNRS, and Ministère français de la Recherche. The authors wish to thank François Garnier (Ecole Nationale Veterinaire de Lyon, Marcy l’Etoile, France), Luc Humbert and Michel Lhermitte (CHR&U de Lille, Lille, France), and Nolwenn Le Meur (INSERM U533, Nantes, France). The excellent technical assistance of Jean-Marie Heslan (INSERM U437, Nantes), Martine Le Cunff, Marie-Jo Louérat, and Béatrice Le Ray (INSERM U533) is also acknowledged. The authors are very grateful to Colleen Clancy (Columbia University, New York, NY) for critical reading of the manuscript.

	Footnotes

 
The first 2 authors contributed equally to this work.

An online-only Data Supplement is available at http://www.circulationaha.org

	References

Top Abstract Introduction Methods Results Discussion References

 
1. Singh BN, Vaughan Williams EM. The effect of amiodarone, a new anti-anginal drug, on cardiac muscle. Br J Pharmacol. 1970; 39: 657–667.[Medline] [Order article via Infotrieve]

2. Nattel S, Singh BN. Evolution, mechanisms, and classification of antiarrhythmic drugs: focus on class III actions. Am J Cardiol. 1999; 84: 11R–19R.[Medline] [Order article via Infotrieve]

3. Kennedy RL, Griffiths H, Gray TA. Amiodarone and the thyroid. Clin Chem. 1989; 35: 1882–1887.[Abstract/Free Full Text]

4. Drvota V, Blange I, Haggblad J, et al. Desethylamiodarone prolongation of cardiac repolarization is dependent on gene expression: a novel antiarrhythmic mechanism. J Cardiovasc Pharmacol. 1998; 32: 654–661.[CrossRef][Medline] [Order article via Infotrieve]

5. Le Bouter S, Demolombe S, Chambellan A, et al. Microarray analysis reveals complex remodeling of cardiac ion channel expression with altered thyroid status: relation to cellular and integrated electrophysiology. Circ Res. 2003; 92: 234–242.[Abstract/Free Full Text]

6. Shahrara S, Drvota V. Thyroid hormone 1 and ß1 receptor mRNA are downregulated by amiodarone in mouse myocardium. J Cardiovasc Pharmacol. 1999; 34: 261–267.[CrossRef][Medline] [Order article via Infotrieve]

7. Gotzsche LB, Orskov H. Cardiac triiodothyronine nuclear receptor binding capacities in amiodarone-treated, hypo- and hyperthyroid rats. Eur J Endocrinol. 1994; 130: 281–290.[Abstract/Free Full Text]

8. Shaikh NA, Downar E, Butany J. Amiodarone, an inhibitor of phospholipase activity: a comparative study of the inhibitory effects of amiodarone, chloroquine and chlorpromazine. Mol Cell Biochem. 1987; 76: 163–172.[Medline] [Order article via Infotrieve]

9. Grossman M, Dobrev D, Kirch W. Amiodarone causes endothelium-dependent vasodilation in human hand veins in vivo. Clin Pharmacol Ther. 1998; 64: 302–311.[CrossRef][Medline] [Order article via Infotrieve]

10. Futamura Y. Effect of amiodarone on cytokine release and on enzyme activities of mouse alveolar macrophages, bone marrow macrophages, and blood monocytes. J Toxicol Sci. 1996; 21: 125–134.[Medline] [Order article via Infotrieve]

11. Xu H, Guo W, Nerbonne JM. Four kinetically distinct depolarization-activated K⁺ currents in adult mouse ventricular myocytes. J Gen Physiol. 1999; 113: 661–678.[Abstract/Free Full Text]

12. Barbieri E, Conti F, Zampieri P, et al. Amiodarone and desethylamiodarone distribution in the atrium and adipose tissue of patients undergoing short- and long-term treatment with amiodarone. J Am Coll Cardiol. 1986; 8: 210–213.[Abstract]

13. Giardina EG, Schneider M, Barr ML. Myocardial amiodarone and desethylamiodarone concentrations in patients undergoing cardiac transplantation. J Am Coll Cardiol. 1990; 16: 943–947.[Abstract]

14. Patterson E, Walden KM, Khazaeli MB, et al. Cardiac electrophysiologic effects of acute and chronic amiodarone administration in the isolated perfused rabbit heart: altered thyroid hormone metabolism. J Pharmacol Exp Ther. 1986; 239: 179–184.[Abstract/Free Full Text]

15. Kodama I, Kamiya K, Toyama J. Cellular electropharmacology of amiodarone. Cardiovasc Res. 1997; 35: 13–29.[Free Full Text]

16. Nattel S. Pharmacodynamic studies of amiodarone and its active N-desethyl metabolite. J Cardiovasc Pharmacol. 1986; 8: 771–777.[Medline] [Order article via Infotrieve]

17. Singh BN. Antiarrhythmic actions of amiodarone: a profile of a paradoxical agent. Am J Cardiol. 1996; 78: 41–53.[Medline] [Order article via Infotrieve]

18. Gallagher JD, Bianchi J, Gessman LJ. A comparison of the electrophysiologic effects of acute and chronic amiodarone administration on canine Purkinje fibers. J Cardiovasc Pharmacol. 1989; 13: 723–729.[Medline] [Order article via Infotrieve]

19. Sun W, Sarma JS, Singh BN. Electrophysiological effects of dronedarone (SR33589), a noniodinated benzofuran derivative, in the rabbit heart: comparison with amiodarone. Circulation. 1999; 100: 2276–2281.[Abstract/Free Full Text]

20. Greenberg ML, Lerman BB, Shipe JR, et al. Relation between amiodarone and desethylamiodarone plasma concentrations and electrophysiologic effects, efficacy and toxicity. J Am Coll Cardiol. 1987; 9: 1148–1155.[Abstract]

21. Huikuri HV, Yli-Mayry S. Frequency dependent effects of d-sotalol and amiodarone on the action potential duration of the human right ventricle. Pacing Clin Electrophysiol. 1992; 15: 2103–2107.[CrossRef][Medline] [Order article via Infotrieve]

22. Sager PT, Uppal P, Follmer C, et al. Frequency-dependent electrophysiologic effects of amiodarone in humans. Circulation. 1993; 88: 1063–1071.[Abstract/Free Full Text]

23. Guo W, Kamiya K, Toyama J. Evidences of antagonism between amiodarone and triiodothyronine on the K⁺ channel activities of cultured rat cardiomyocytes. J Mol Cell Cardiol. 1997; 29: 617–627.[CrossRef][Medline] [Order article via Infotrieve]

24. Varró A, Virag L, Papp JG. Comparison of the chronic and acute effects of amiodarone on the calcium and potassium currents in rabbit isolated cardiac myocytes. Br J Pharmacol. 1996; 117: 1181–1186.[Medline] [Order article via Infotrieve]

25. Kamiya K, Nishiyama A, Yasui K, et al. Short- and long-term effects of amiodarone on the two components of cardiac delayed rectifier K⁺ current. Circulation. 2001; 103: 1317–1324.[Abstract/Free Full Text]

26. Gotzsche LB. ß-Adrenergic receptors, voltage-operated Ca²⁺-channels, nuclear triiodothyronine receptors and triiodothyronine concentration in pig myocardium after long-term low-dose amiodarone treatment. Acta Endocrinol (Copenh). 1993; 129: 337–347.[Medline] [Order article via Infotrieve]

27. Hanlon MR, Wallace BA. Structure and function of voltage-dependent ion channel regulatory ß-subunits. Biochemistry. 2002; 41: 2886–2894.[CrossRef][Medline] [Order article via Infotrieve]

28. Singh BN, Nademanee K. Amiodarone and thyroid function: clinical implications during antiarrhythmic therapy. Am Heart J. 1983; 106: 857–869.[CrossRef][Medline] [Order article via Infotrieve]

29. Lambert C, Cardinal R, Vermeulen M, et al. Lack of relation between the ventricular refractory period prolongation by amiodarone and the thyroid state in rats. J Pharmacol Exp Ther. 1987; 242: 320–325.[Abstract/Free Full Text]

30. Bosch RF, Li GR, Gaspo R, et al. Electrophysiologic effects of chronic amiodarone therapy and hypothyroidism, alone and in combination, on guinea pig ventricular myocytes. J Pharmacol Exp Ther. 1999; 289: 156–165.[Abstract/Free Full Text]

31. Bakker O, Hudig F, Meijssen S, et al. Effects of triiodothyronine and amiodarone on the promoter of the human LDL receptor gene. Biochem Biophys Res Commun. 1998; 249: 517–521.[CrossRef][Medline] [Order article via Infotrieve]

32. van Beeren HC, Bakker O, Wiersinga WM. Desethylamiodarone interferes with the binding of co-activator GRIP-1 to the ß1-thyroid hormone receptor. FEBS Lett. 2000; 481: 213–216.[CrossRef][Medline] [Order article via Infotrieve]

This article has been cited by other articles:

				N. Yamashita, T. Kaku, T. Uchino, S. Isomoto, H. Yoshimatsu, and K. Ono Short- and Long-Term Amiodarone Treatments Regulate Cav3.2 Low-Voltage-Activated T-type Ca2+ Channel through Distinct Mechanisms Mol. Pharmacol., May 1, 2006; 69(5): 1684 - 1691. [Abstract] [Full Text] [PDF]

				A.-L. Leoni, C. Marionneau, S. Demolombe, S. L. Bouter, M. E. Mangoni, D. Escande, and F. Charpentier Chronic heart rate reduction remodels ion channel transcripts in the mouse sinoatrial node but not in the ventricle Physiol Genomics, December 14, 2005; 24(1): 4 - 12. [Abstract] [Full Text] [PDF]

				S. Demolombe, C. Marionneau, S. Le Bouter, F. Charpentier, and D. Escande Functional genomics of cardiac ion channel genes Cardiovasc Res, August 15, 2005; 67(3): 438 - 447. [Abstract] [Full Text] [PDF]

				N. Gaborit, M. Steenman, G. Lamirault, N. Le Meur, S. Le Bouter, G. Lande, J. Leger, F. Charpentier, T. Christ, D. Dobrev, et al. Human Atrial Ion Channel and Transporter Subunit Gene-Expression Remodeling Associated With Valvular Heart Disease and Atrial Fibrillation Circulation, July 26, 2005; 112(4): 471 - 481. [Abstract] [Full Text] [PDF]

				C. Marionneau, B. Couette, J. Liu, H. Li, M. E. Mangoni, J. Nargeot, M. Lei, D. Escande, and S. Demolombe Specific pattern of ionic channel gene expression associated with pacemaker activity in the mouse heart J. Physiol., January 1, 2005; 562(1): 223 - 234. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Data Supplement All Versions of this Article: 110/19/3028    most recent 01.CIR.0000147187.78162.ACv1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Le Bouter, S. Articles by Demolombe, S. Search for Related Content PubMed PubMed Citation Articles by Le Bouter, S. Articles by Demolombe, S. Related Collections Functional genomics Ion channels/membrane transport Physiological and pathological control of gene expression